DOCSLIB.ORG

Chronic Pentamidine Aerosol Prophylaxis Does Not Induce QT Prolongation *

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chronic Pentamidine Aerosol Prophylaxis Does Not Induce QT Prolongation * ©linical Volume 71 -1993 Investigator Continuation of Klinische Wochenschrift ij Uta* G 2- &<? Editor in Chief N. Zöllner, Munich Associate Editor U. Gresser, Munich 19 $3 • -7 - Editorial Board G. Seifert, Hamburg Mainz G.Adler, Ulm J. Shepherd, Glasgow M.J. Mihatsch, Basle M.E. Bertrand, Lille H. B. Stähelin, Basle B. S. Mitchell, Chapel Hill T. Brandt, Munich K.-H. Usadel, Frankfurt a.M. C. Mueller-Eckhardt, Gießen V. Diehl, Cologne G. Vantrappen, Louvain O.-A. Müller, Munich Ε. Erdmann, Munich R von Wiehert, Marburg J.G. Puig, Madrid W. Gerok, Freiburg K.G. Wormsley, Dundee E.O. Riecken, Berlin G. Giebisch, New Haven E. Ritz, Heidelberg F. -D. Goebel, Munich Advisory Board R. Ritz, Basle D. Häussinger, Freiburg S. Sacks, London R. Arnold, Marburg H. Kaess, Munich H. Schuster, Munich J.R. Kalden, Erlangen W.G. Daniel, Hannover H.-R Schuster, Hildesheim G. J. Krejs, Graz J. Dichgans, Tübingen W. Seeger, Glessen W. Kubier, Heidelberg A. Distler, Berlin H.-G. Sieberth, Aachen H. Löffler, Kiel H. L Fehm, Lübeck R-A. Spengel, Munich F. Loogen, Düsseldorf R. Ferlinz, Mainz G. Steinbeck, Munich W. Lorenz, Marburg O. Götze, Göttingen J.A.Tischfield, Indianapolis J. Lubsen, Rotterdam RA. Gries, Düsseldorf G. Utermann, Innsbruck P.M. Mannucci, Milan W.L. Gross, Lübeck/Bad Bramstedt H. Vetter, Bonn RA. Miescher, Geneva E.G. Hahn, Erlangen C. Wagener, Hamburg G. Paumgartner, Munich H.-L. Hahn, Wiesbaden M. Wienbeck, Augsburg D. Hoelzer, Frankfurt a.M. H. D. Pohle, Berlin G. Wolfram, Munich C. Keller, Munich D.L. Scott, London R. Ziegler, Heidelberg RC. Scriba, Munich HJ. Kramer, Bonn Springer International Continuation of Klinische Wochenschrift Founded in 1922. Edited by V. Salle, A. Gottstein, A. von Domaris, P. Jungmann, C. von Noorden, H. Schwiegk, among others. From 1926, official journal of the Gesellschaft Deutscher Naturforscher und Ärzte. Berlin, Springer, and Munich, J.F. Bergmann. Was the continuation of the Berliner Klinische Wochenschrift, edited from 1864 to 1920 by L.C. Posner, L. Waldenburg, and CA. Ewald, etc. and published by A. Hirschwald in Berlin, and Therapeutischen (Halb-)Monatsheft, edited by W. Heubner, L. Langstein, and E. Meyer, 1887-1921, Springer, Berlin. Copyright Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review or thesis), that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders. All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher. The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Special regulations for photocopies in the USA: Photocopies may be made for personal or in-house use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0941-0198, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher. Printers: Universitätsdruckerei Η. Stürtz AG, Würzburg © Springer-Verlag Berlin Heidelberg 1993 Printed in Germany Bianchi L -* Reichen J Contents of Volume 71 Biber J Murer Η Bieg S -* Kling Ε No 1: pp 1- 90 published January 22, 1993 Birbamer G Berek Κ No 2:pp 91- 176 published February 8, 1993 Birk A -* Kiese wetter Η No 3: pp 177- 256 published March 4, 1993 Bittinger A -> Wagner U No 4: pp 257- 338 published April 1, 1993 Bleich Μ -»> Greger R No 5: pp 339- 420 published May 3, 1993 Blind Ε, Raue F, Meinel T, Bucher M, No 6: pp 421- 504 published June 9, 1993 Manegold C, Ebert W, Vogt-Moykopf I, No 7: pp 505- 586 published July 5, 1993 Ziegler R: Levels of parathyroid hor­ No 8: pp 587- 672 published August 9, 1993 mone-related protein in hypercalcemia No 9: pp 673- 762 published September 1, 1993 of malignancy: comparison of midre- No 10: pp 763- 874 published October 1,1993 gional radioimmunoassay and two-site No 11: pp 875- 962 published November 2, 1993 immunoradiometric assay 31 No 12: pp 963-1022 published December 2, 1993 Blume J -* Kiesewetter Η Supplement to Volume 71/lssue 5: Renin-angiotensin-system and collagen metabolism Bock HL Nothdurft HD in diabetes mellitus and arterial hypertension, Heidelberg, November 6-8, 1992 Boehm BO, Farid NR: Molecular aspects Supplement to Volume 71/lssue 8: Seventh International Symposium on The Biomedical of endocrine autoimmunity 79 and Clinical Aspects of Coenzyme Q, Copenhagen, September 18-19, 1992 Boehm BO, Kühnl Ρ, Löliger C, Ketzler- Sasse U, Holzberger G, Seidl S, Bäuerle R, Schifferdecker Ε, Usadel KH: HLA- DR3 and HLA-DR5 confer risk for au­ toantibody positivity against the thyro- peroxidase (mic-TPO) antigen in healthy blood donors 221 Abedinpour F Weber MM Ball F Böhles Η Boehme Μ -> Kling Ε Adelmann Β -> Weber MM Banos V ->· Gomez J Bogner JR -> Papakonstantinou G Adler G -• Scherbaum WA Barrett PHR -• Parhofer KG Bogner JR -> Thalhammer C Aguilar-Martinez JL Cantero-Hinojosa Barrio J -*• Domingo Ρ Bohle A -* Kirsten D J Barth PJ Wagner U Böhles Η, Aschenbrenner Μ, Roth Μ, Albrecht H, Stellbrink H-J, Fenske S, Koch Baschieri L -»· Monzani F Loewenich V ν, Ball F, Usadel KH: De­ J, Greten H: A novel variety of atypical Bassermann R Dörfler Η velopment of thyroid gland volume dur­ Pneumocystis carinii infection after Bäuerle R -> Boehm BO ing the first 3 months of life in breast-fed longterm prophylactic pentamidine in­ Baum Κ -• Essfeld D versus iodine-supplemented and iodine- halation in an AIDS patient: large lower Baumann Μ ->> Graeve L free formula-fed infants 13 lobe pneumocystoma 310 Baumbach A -> Preisack MB Bokemeyer D -> Meyer-Lehnert Η Albrecht Η Plettenberg A Baumert T, Kleber G, Schwarz J, Stäbler Bollensen Ε, Menck S, Buzanoski J, Alexander GJM Arnold JC A, Lamerz R, Mann K: Reversible hyper• Prange HW: Iatrogenic epidural spinal Algra A Oddens BJ kinesia in a patient with autoimmune po• abscess 780 Allende MT Collazos J lyglandular syndrome type I 924 Borlinghaus P, Wieser S, Lamerz R: Epi­ Allgayer Η -» Scheurlen C Baumgarten R von Hofstetter-Degen Κ dermal growth factor, transforming Allolio Β Lehmann R Baumgarten R von ->· Wetzig J growth factor-or, and epidermal growth Althoff P-H -> Rau Η Baur Μ -»· Glasbrenner Β factor receptor content in normal and Ammon A, Eiffert H, Reil S, Beyer J-H, Bause HW Scholz J carcinomatous gastric and colonic tis­ Droese M, Hiddemann W: Tumor-asso­ Beaujean R -> Reitz G sue 903 ciated antigens in effusions of malignant Bechtel U -+ Christ Μ Borst HG, Schäfers H-J: Lung transplanta• and benign origin 437 Beck M, Valadares ER, Lötz J: Gaucher's tion 98 Andreas S, Breska Β von, Kopp Ε, Figulla disease: therapy by intravenous infu• Brandis Μ, Hardt Κ ν d, Zimmerhackl RB, HR, Kreuzer Η: Periodic respiration in sions of modified glucocerebrosidase Mohrmann Μ, Leititis J: Cytostatics - in­ patients with heart failure 281 78 duced tubular toxicity 855 Appenheimer Μ -> Ko Υ Becker Η -> Gross-Weege W Brandis Μ Pfleiderer S Arnim Τ von Pliml W Becker W -> Raue F Brandl Η -• Ritter C von Arnold JC, Nouri-Aria KT, O'Grady JG, Beimpold Η -> Wiedermann CJ Braun W -» Weber Β Portmann BC, Alexander GJM, Williams Bein Β -»· Sailer Β Braunsteiner Η -> Wiedermann CJ R: Hepatic α-interferon expression in cy- Benker G Jaspers C Brecht-Krauß D Glasbrenner Β tomegalovirus-infected liver allograft Benker G -• Petrasch SG Breckenridge A: Clinical pharmacology in recipients with and without vanishing Benning Κ -• Müller-Ladner U the 1990s: a personal perspective 478 bile duct syndrome 191 Berchtenbreiter U -+ Körting HC Breska Β von -* Andreas S Aschenbrenner Μ -> Böhles Η Berek Κ, Kiechl S, Willeit J, Birbamer G, Brodersen H-P -» Holtkamp W Athanasiadis A -> Preisack MB Vogl G, Schmutzhard E: Subarachnoid Brosen K: The pharmacogenetics of the hemorrhage as presenting feature of selective serotonin reuptake inhibitors Baartz F-J -»· Kirsch ΚΑ isolated neurosarcoidosis 54 1002 Bach D -»· Heering Ρ Bergelson LD: Gangliosides and antitu­ Bucher Μ Blind Ε Bach R Jung F mor immunity 590 Buettner UW -* Stumvoll Μ Badenhoop Κ -> Rau Η Berger J -*· Lenzhofer R
Load more

Recommended publications
  • United States Patent Office Patented Apr
    3,505,222 United States Patent Office Patented Apr. 7, 1970 1. 2 3,505,222 product of a mercaptain with sulfur trioxide. Their metal LUBRICANT COMPOSITIONS salts are represented by the formula: Leonard M. Niebylski, Birmingham, Mich, assignor to O Ethyl Corporation, New York, N.Y., a corporation of Virginia (R-S-S-0--M No Drawing. Filed Mar. 29, 1967, Ser. No. 626,701 5 s (I) Int. C. C10m 5/14, 3/18, 7/36 wherein R is a hydrocarbon radical containing from 1 U.S. C. 252-17 2 Claims to about 30 carbon atoms, M is a metal, and n is the valence of metal M. For example, when M is the monova 0. lent sodium ion, n is 1. ABSTRACT OF THE DISCLOSURE The radical R can be an alkyl, cycloalkyl, aralkyl, The extreme pressure wear properties of base lubri alkaryl, or aryl radical. The radicals may contain other cants including water, hydrocarbons, polyesters, silicones, nonhydrocarbon substituents such as chloro, bromo, iodo, polyethers and halocarbons is enhanced by the addition fluoro, nitro, hydroxyl, nitrile, isocyanate, carboxyl, car of a synergistic mixture of a thiosulfate compound and 15 bonyl, and the like. a lead compound. The useful metals are all those capable of forming Bunte salts. Preferred metals are those previously listed as suitable for forming metal thiosulfates. Of these, the Background more preferred metals are sodium and lead, and lead is 20 the most preferred metal in the Bunte salts. This invention relates to improved lubricant composi Examples of useful Bunte salts include: tions.
    [Show full text]
  • University of California Riverside
    UNIVERSITY OF CALIFORNIA RIVERSIDE Natamycin, a New Postharvest Biofungicide: Toxicity to Major Decay Fungi, Efficacy, and Optimized Usage Strategies A Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Plant Pathology by Daniel Sungen Chen September 2020 Dissertation Committee: Dr. James E. Adaskaveg, Chairperson Dr. Michael E. Stanghellini Dr. Alexander I. Putman Copyright by Daniel Sungen Chen 2020 The Dissertation of Daniel Sungen Chen is approved: Committee Chairperson University of California, Riverside AKNOWLEDGEMENTS Foremost, I thank my mentor Dr. James E. Adaskaveg for accepting me into his research program and teaching me the intricacies of the field of postharvest plant pathology and preparing me for a bright career ahead. His knowledge of the field is unmatched. A special thanks goes out to Dr. Helga Förster, whose expertise and attention to detail has helped me out tremendously in my research and writings. I thank my dissertation committee members, Dr. Michael Stanghellini and Dr. Alexander Putman, for their time spent reviewing my dissertation and their guidance during the pursuit of my doctoral degree. Special thanks also go out to my lab members Dr. Rodger Belisle, Dr. Wei Hao, Dr. Kevin Nguyen, and Nathan Riley for their companionship and much appreciated help with my projects. I would also like to thank my former laboratory members, Dr. Stacey Swanson and Dr. Morgan Thai for their guidance and help during the early years of my graduate program. Thanks go out to Dr. Lingling Hou, Dr. Yong Luo, and Doug Cary for their assistance with performing experimental packingline studies at the Kearney Agricultural Research and Extension Center.
    [Show full text]
  • Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives
    Current Fungal Infection Reports (2019) 13:45–58 https://doi.org/10.1007/s12281-019-00338-6 PHARMACOLOGY AND PHARMACODYNAMICS OF ANTIFUNGAL AGENTS (N BEYDA, SECTION EDITOR) Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives Ruchi Thakkar1,2 & Akash Patil1,2 & Tabish Mehraj1,2 & Narendar Dudhipala1,2 & Soumyajit Majumdar1,2 Published online: 2 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review In this review, a compilation on the current antifungal pharmacotherapy is discussed, with emphases on the updates in the formulation and clinical approaches of the routinely used antifungal drugs in ocular therapy. Recent Findings Natamycin (Natacyn® eye drops) remains the only approved medication in the management of ocular fungal infections. This monotherapy shows therapeutic outcomes in superficial ocular fungal infections, but in case of deep-seated mycoses or endophthalmitis, successful therapeutic outcomes are infrequent, as a result of which alternative therapies are sought. In such cases, amphotericin B, azoles, and echinocandins are used off-label, either in combination with natamycin or with each other (frequently) or as standalone monotherapies, and have provided effective therapeutic outcomes. Summary In recent times, amphotericin B, azoles, and echinocandins have come to occupy an important niche in ocular antifungal pharmacotherapy, along with natamycin (still the preferred choice in most clinical cases), in the management of ocular fungal infections.
    [Show full text]
  • Magnetic Graphene Oxide Modified by Chloride Imidazole Ionic Liquid For
    RSC Advances View Article Online PAPER View Journal | View Issue Magnetic graphene oxide modified by chloride imidazole ionic liquid for the high-efficiency Cite this: RSC Adv.,2017,7,9079 adsorption of anionic dyes† Huan Wangab and Yinmao Wei*a Magnetic graphene oxide modified with 1-amine-3-methyl imidazole chloride ionic liquid (LI-MGO) was prepared through chemical co-precipitation and modified using 1-amine-3-imidazolium chloride ionic liquid. The as-prepared LI-MGO was characterized using X-ray diffraction (XRD), transmission electron microscopy (TEM) and Fourier transform infrared spectrometry (FT-IR). The adsorption properties were evaluated through adsorption experiments with two kinds of anionic dyes, orange IV (OIV) and glenn black R (GR) and two kinds of cationic dyes, acridine orange (AO) and crystal violet (CV). The results indicated that the adsorption data fitted the Langmuir isotherm and followed pseudo-second-order kinetics. The maximum adsorption capacities for GR, OIV, AO and CV were 588.24, 57.37, 132.80 and Received 29th November 2016 À1 Creative Commons Attribution 3.0 Unported Licence. 69.44 mg g at 298 K, respectively. LI-MGO has better selective adsorption for anionic dyes than Accepted 17th January 2017 magnetic graphene oxide (MGO) due to electrostatic interactions. Moreover, the LI-MGO adsorbent can DOI: 10.1039/c6ra27530c be magnetic separated and is easy to prepare. It demonstrated that LI-MGO would have great potential rsc.li/rsc-advances as an efficient environmentally friendly adsorbent for the removal of anionic
    [Show full text]
  • Synthesis of Photoreactive Imidazole Derivatives and Thermal Curing Reaction of Epoxy Resins Catalyzed by Photo-Generated Imidazole
    Polymer Journal, Vol. 29, No. 5, pp 450-456 (1997) Synthesis of Photoreactive Imidazole Derivatives and Thermal Curing Reaction of Epoxy Resins Catalyzed by Photo-Generated Imidazole Tadatomi NrsHIKUBO,t Atsushi KAMEYAMA, and Yoshiyasu TOYA Department of' Applied Chemistry, Faculty of Engineering, Kanagawa University, Rokkakubashi, Kanagawa-ku, Yokohama, 221 Japan (Received November 6, 1996) ABSTRACT: Photoreactive blocked imidazoles such as N-(2-nitrobenzyloxycarbonyl)imidazole (2-NBCI), N-(3-nitro­ benzyloxycarbonyl)imidazole (3-NBCI), N-( 4-nitrobenzyloxycarbonyl)imidazole (4- NBCI), N-( 4-chloro-2-nitro benzyloxy­ carbonyl )imidazole (CNBCI), N-(5-methyl-2-nitrobenzyloxycarbonyl)imidazole (MNBCI), and N-(4,5-dimethoxy-2-ni­ trobenzyloxycarbonyl)imidazole (DNBCI) were synthesized in good yields by reactions of N,N'-carbonyldiimidazole (CDI) with corresponding benzyl alcohols. The prepared 2-NBCI decomposed smoothly to produce imidazole by UV-irradiation in tetrahydrofuran (THF) solution or poly(methyl methacrylate) (PMMA) film. Rates of photolysis of DNBCI, MNBCI and CNBCI were higher than that of 2-NBCI in PMMA film, although the rates of 3-NBCI and 4-NBCI were slower than that of 2-NBCI in PMMA film under the same conditions. Thermal curing reactions of epoxy resins and poly(glycidyl methacrylate-co-methyl methacrylate) [P(GMA55-MMA45)] using photo-generated imidazole were examined at I00-160°C. The ring opening reaction of epoxide groups, confirmed by IR spectra, in epoxy resins and P(GMA55-MMA45) proceeded smoothly by catalysis of the photo-generated imidazole. KEY WORDS Synthesis of Blocked Imidazole /Photo-Generation/ Imidazole / Thermal Curing Reaction / Epoxy Resin/ Poly(glycidyl methacrylate-co-methyl methac!ylate) / Epoxy resins are typical thermo-setting resins, and Tsunooka et al.
    [Show full text]
  • 5.2 Protein Purification
    Protein purification Purification of a His6-tagged Green Fluorescent Protein (GFP) 5.2 Protein purification 5.2.1 Purification of a His6-tagged Green Fluorescent Protein (GFP) Principle You can add either a N- or C-terminal His6-tag to the protein that you want to express if nd you use the RTS pIVEX His6-tag 2 generation vector set (pIVEX2.3d; pIVEX2.4d, see Chapter 2.4.2.1) or the RTS E. coli Linear Template Generation Set, His6-tag (see Chapter 2.3.3.1). These His6-tagged proteins can be purified in one step by immobilized metal affinity chromatography (IMAC) (Ford, C. F. et al., 1991) on a nickel-nitrilotriacetic acid (Ni- NTA) column. In a single step, this affinity matrix can purify a protein (starting concen- tration less than 1% of the total protein) to more than 95% homogeneity. Nitrilotriacetic acid (NTA) is a tetradentate chelating adsorbent developed by Roche Diagnostics GmbH. NTA occupies four of six ligand binding sites of the nickel ion, leav- ing two sites free for interaction with the His6-tag. NTA binds metal ions tightly, allowing use of stringent washes. Histidine residues on the tag, connected via a short linker to the C- or N-terminus of the protein, bind to the Ni-ions. The protein can be eluted by competitive displacement with 55 imidazole. Note: Since Ni-NTA is not as selective as other affinity chromatography matrices, it may also bind proteins with exposed patches of histidine, cysteine or tryptophan residues. Therefore elution conditions must be optimized for each protein.
    [Show full text]
  • Effect of Salicylates on Histamine and L-Histidine Metabolism. Inhibition of Imidazoleacetate Phosphoribosyl Transferase
    Effect of salicylates on histamine and L-histidine metabolism. Inhibition of imidazoleacetate phosphoribosyl transferase. J Moss, … , M Vaughan, M A Beaven J Clin Invest. 1976;58(1):137-141. https://doi.org/10.1172/JCI108442. Research Article In man and other animals, urinary excretion of the histidine and histamine metabolite, imidazoleacetate, is increased and that of its conjugated metabolite, ribosylimidazoleacetate, decreased by salicylates. Imidazoleacetate has been reported to produce analgesia and narcosis. Its accumulation as a result of transferase inhibition could play a part in the therapeutic effects of salicylates. To determine the locus of salicylate action, we have investigated the effect of anti- inflammatory drugs on imidazoleacetate phosphoribosyl transferase, the enzyme that catalyzes the ATP-dependent conjugation of imidazoleacetate with phosphoribosylpyrophosphate. As little as 0.2 mM aspirin produced 50% inhibition of the rat liver transferase. In vivo, a 30% decrease in the urinary excretion of ribosylimidazoleacetate has been observed with plasma salicylate concentrations of 0.4 mM. The enzyme was also inhibited by sodium salicylate but not by salicylamide, sodium gentisate, aminopyrine, phenacetin, phenylbutazone, or indomethacin. The last four drugs have been shown previously not to alter the excretion of ribosylimidazoleacetate when administered in vivo. Since both the drug specificity and inhibitory concentrations are similar in vivo and in vitro, it seems probable that the effect of salicylates on imidazoleacetate conjugation results from inhibition of imidazoleacetate phosphoribosyl transferase. Find the latest version: https://jci.me/108442/pdf Effect of Salicylates on Histamine and L-Histidine Metabolism INHIBITION OF IMIDAZOLEACETATE PHOSPHORIBOSYL TRANSFERASE JOEL MOSS, MARIA C. DE MELLO, MARTHA VAUGHAN, and MICHAEL A.
    [Show full text]
  • Fexinidazole Tablets Occurs in a Concentration-Dependent Manner
    HIGHLIGHTS OF PRESCRIBING INFORMATION • QT Interval Prolongation: Prolongation of the QT interval due to These highlights do not include all the information needed to use Fexinidazole Tablets occurs in a concentration-dependent manner. Avoid FEXINIDAZOLE TABLETS safely and effectively. See full prescribing use in patients with known prolongation, proarrhythmic conditions, and information for FEXINIDAZOLE TABLETS. concomitant use with drugs that prolong the QT interval, those that block cardiac potassium channels, and/or those that induce bradycardia, or are FEXINIDAZOLE tablets, for oral use inducers of hepatic CYP450. (5.2, 7.1, 7.2, 12.2) Initial U.S. Approval: 2021 • Neuropsychiatric Adverse Reactions: Adverse reactions such as agitation, ----------------------------INDICATIONS AND USAGE--------------------------- anxiety, abnormal behavior, depression, suicidal ideation, nightmares, Fexinidazole Tablets is a nitroimidazole antimicrobial, indicated for the hallucination, and personality change have been observed during therapy. treatment of both first-stage (hemolymphatic) and second-stage Inform patients and their caregivers of the risk. Consider alternative (meningoencephalitic) human African trypanosomiasis (HAT) due to therapy or increased monitoring of the patient, including hospitalization in Trypanosoma brucei gambiense in patients 6 years of age and older and patients with psychiatric disorders, or if these adverse reactions occur. (5.3) weighing at least 20 kg. (1) • Neutropenia: Avoid concomitant use of drugs which may cause Limitations of Use neutropenia and monitor leukocyte count periodically. Monitor patients Due to the decreased efficacy observed in patients with severe second stage with neutropenia for symptoms or signs of infection. (5.4, 6.1) HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/µL) • Potential for Hepatotoxicity: Evaluate liver-related laboratory tests at the due to T.
    [Show full text]
  • Natamycin As an Allowed Nonsynthetic Substance
    Technology Sciences Group Inc. 712 Fifth St., Suite A Davis, CA 95616 Direct: (530) 601-5064 Fax: (530) 757-1299 E-Mail: [email protected] Jacob S. Moore Regulatory Consultant September 1, 2016 USDA/AMS/NOP, Standards Division 1400 Independence Ave. SW Room 2648-So., Ag Stop 0268 Washington, DC 20250-0268 Attention: Lisa Brines, PhD National List Manager RE: National Organic Program Petition for Classification of Natamycin as an Allowed Nonsynthetic Substance Dear Dr. Brines: Technology Sciences Group Inc., on behalf of DSM Food Specialties B.V., submits the enclosed petition for classification of natamycin as an allowed nonsynthetic substance. Natamycin is a naturally-occurring compound produced by fermentation of Streptomyces natalensis. As natamycin is known to the National Organic Program and National Organic Standards Board, the petitioner requests that a focused Technical Report be issued to complement the work previously done and resolve the classification status of the petitioned substance. Please contact me with any questions or concerns. Jacob S. Moore TITLE Petition for Classification of Natamycin as an Allowed Nonsynthetic Substance in Organic Crop Production AUTHOR Technology Sciences Group Inc. DATE September 1, 2016 Page 1 of 212 Natamycin Allowed Nonsynthetic Petition – National Organic Program – September 1, 2016 Table of Contents Item A—Indicate which section or sections the petitioned substance will be included on and/or removed from the National List. .................................................................................................................................
    [Show full text]
  • Imidazole and Its Biological Activities: a Review
    Available online a t www.pelagiaresearchlibrary.com Pelagia Research Library Der Chemica Sinica, 2010, 1 (3): 36-47 ISSN: 0976-8505 CODEN (USA) CSHIA5 Imidazole and its biological activities: A review Kumari Shalini*, Pramod Kumar Sharma, Nitin Kumar Department of Pharmaceutical Technology, Meerut Institute of Engineering & Technology, Meerut (UP), India ______________________________________________________________________________ ABSTRACT Imidazole is a planer five-member heterocyclic ring with 3C and 2N atom and in ring N is present in 1 st and 3 rd positions. The imidazole ring is a constituent of several important natural products, including purine, histamine, histidine and nucleic acid. Being a polar and ionisable aromatic compound, it improves pharmacokinetic characteristics of lead molecules and thus used as a remedy to optimize solubility and bioavailability parameters of proposed poorly soluble lead molecules. Imidazole derivatives have occupied a unique place in the field of medicinal chemistry. The incorporation of the imidazole nucleus is an important synthetic strategy in drug discovery. The high therapeutic properties of the imidazole related drugs have encouraged the medicinal chemists to synthesize a large number of novel chemotherapeutic agents. Imidazole drugs have broadened scope in remedying various dispositions in clinical medicines. Numerous methods for the synthesis of imidazole and also their various structure reactions offer enormous scope in the field of medicinal chemistry. This articles aims to review the
    [Show full text]
  • FEXINIDAZOLE and VL-2098 SHYAM SUNDAR Target Product Profile for a NCE
    SMe N O N CH O 2 N 2 Me NITROIMIDAZOLES FOR VISCERAL LEISHMANIASIS – FEXINIDAZOLE AND VL-2098 SHYAM SUNDAR Target Product Profile for a NCE Optimal Target Profile Minimal Target Profile Target Label VL and PKDL VL Spp All species L. donavani Distribution All areas Either India or Africa Target Population Immunocompetent and Immunocompetent immunosuppressed Clinical Efficacy > 95% > 90% Resistance Active against resistant strains Safety and No AEs requiring monitoring 1 monitoring visit in mid/end - point Tolerability Contraindications None Pregnancy/lactation Interactions None - Compatible for None for malaria, TB, and HIV combination therapy concomitant therapies Formulation Oral / im depot Oral / im depot Treatment Regimen 1/day for 10 days po/ 3 shots bid for <10 days po; or >3 shots over 10 days* over 10 days Stability 3 yrs in zone 4 Stable under conditions that can be reasonably achieved in the target region (> 2 yr) Cost < $10 / course <$80 / course Fexinidazole • Discovery : 1970 HOE 239, discontinued 1980 • Chemical Name: 1H-imidazole,1-methyl-2-[[4- methylthio) phenoxy] methyl] 5-nitro-imidazole SMe • Metabolism N O N CH O 2 N 2 Me N CYP N N CH O SCH O2N 2 3 O N CH O SOCH3 O N CH O SO CH N 2 N 2 2 N 2 2 3 Me FMO Me Me Fexinidazole Fexinidazole sulfoxide (M1) Fexinidazole sulfone (M2) • PM FEXI = 279 g/mol • PM M1 = 295g/mol • PM M2 = 311g/mol In vitro data of fexinidazole and metabolites on L donovani In vivo data in mice infected with L donovani PK summary § Bioavailability Fexi : rapidly absorbed: median Tmx: 3 – 4 H; mean
    [Show full text]
  • Essentials of Heterocyclic Chemistry-I Heterocyclic Chemistry
    Baran, Richter Essentials of Heterocyclic Chemistry-I Heterocyclic Chemistry 5 4 Deprotonation of N–H, Deprotonation of C–H, Deprotonation of Conjugate Acid 3 4 3 4 5 4 3 5 6 6 3 3 4 6 2 2 N 4 4 3 4 3 4 3 3 5 5 2 3 5 4 N HN 5 2 N N 7 2 7 N N 5 2 5 2 7 2 2 1 1 N NH H H 8 1 8 N 6 4 N 5 1 2 6 3 4 N 1 6 3 1 8 N 2-Pyrazoline Pyrazolidine H N 9 1 1 5 N 1 Quinazoline N 7 7 H Cinnoline 1 Pyrrolidine H 2 5 2 5 4 5 4 4 Isoindole 3H-Indole 6 Pyrazole N 3 4 Pyrimidine N pK : 11.3,44 Carbazole N 1 6 6 3 N 3 5 1 a N N 3 5 H 4 7 H pKa: 19.8, 35.9 N N pKa: 1.3 pKa: 19.9 8 3 Pyrrole 1 5 7 2 7 N 2 3 4 3 4 3 4 7 Indole 2 N 6 2 6 2 N N pK : 23.0, 39.5 2 8 1 8 1 N N a 6 pKa: 21.0, 38.1 1 1 2 5 2 5 2 5 6 N N 1 4 Pteridine 4 4 7 Phthalazine 1,2,4-Triazine 1,3,5-Triazine N 1 N 1 N 1 5 3 H N H H 3 5 pK : <0 pK : <0 3 5 Indoline H a a 3-Pyrroline 2H-Pyrrole 2-Pyrroline Indolizine 4 5 4 4 pKa: 4.9 2 6 N N 4 5 6 3 N 6 N 3 5 6 3 N 5 2 N 1 3 7 2 1 4 4 3 4 3 4 3 4 3 3 N 4 4 2 6 5 5 5 Pyrazine 7 2 6 Pyridazine 2 3 5 3 5 N 2 8 N 1 2 2 1 8 N 2 5 O 2 5 pKa: 0.6 H 1 1 N10 9 7 H pKa: 2.3 O 6 6 2 6 2 6 6 S Piperazine 1 O 1 O S 1 1 Quinoxaline 1H-Indazole 7 7 1 1 O1 7 Phenazine Furan Thiophene Benzofuran Isobenzofuran 2H-Pyran 4H-Pyran Benzo[b]thiophene Effects of Substitution on Pyridine Basicity: pKa: 35.6 pKa: 33.0 pKa: 33.2 pKa: 32.4 t 4 Me Bu NH2 NHAc OMe SMe Cl Ph vinyl CN NO2 CH(OH)2 4 8 5 4 9 1 3 2-position 6.0 5.8 6.9 4.1 3.3 3.6 0.7 4.5 4.8 –0.3 –2.6 3.8 6 3 3 5 7 4 8 2 3 5 2 3-position 5.7 5.9 6.1 4.5 4.9 4.4 2.8 4.8 4.8 1.4 0.6 3.8 4 2 6 7 7 3 N2 N 1 4-position
    [Show full text]